Syndax Pharmaceuticals reported second quarter 2026 financial results ending June 30, 2026. Total revenue reached $72.8 million, a 92% year-over-year increase, driven by Revuforj net revenue of $54.7 million and Niktimvo collaboration revenue of $18.1 million. The company reported a net loss attributable to common stockholders of $49.4 million, or $0.55 per share, for the six months ended June 30, 2026. Syndax maintains a cash position of $575.1 million and expects full-year R&D plus SG&A expenses of approximately $400 million. The company announced new pipeline assets SNDX-4321 for NSCLC and SNDX-62122 for myelofibrosis, with topline data expected in the fourth quarter 2026 from Phase 2 trials of axatilimab in IPF and frontline cGVHD. Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company advancing innovative cancer therapies.

Syndax Pharmaceuticals, Inc. held an R&D event on July 14, 2026, where it issued a press release and presentation highlighting its late-stage programs and R&D strategy, including new pipeline assets. Syndax Pharmaceuticals, Inc. is a biopharmaceutical company focused on oncology-related research and development.

Syndax Pharmaceuticals, Inc. closed a private placement of $250.0 million in 2.25% Convertible Senior Notes due 2031 on June 10, 2026. The company received approximately $243.0 million in net proceeds to be used for general corporate purposes, including research, development, and commercialization. Syndax Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing clinical-stage oncology drugs.

At its June 10, 2026 Annual Meeting, Syndax Pharmaceuticals stockholders approved the 2026 Equity Incentive Plan and the 2026 Employee Stock Purchase Plan (ESPP), both effective immediately. The 2026 Equity Incentive Plan reserves 7,200,000 shares of common stock and includes share recycling provisions for expired or cancelled awards from the 2015 Omnibus Incentive Plan. The 2026 ESPP replaces the 2015 ESPP, providing stock purchase rights for both U.S. and foreign employees, though shares from the 2015 ESPP will not roll over. Stockholders also elected directors, ratified the independent auditor, and approved executive compensation. The company is a biopharmaceutical company that develops therapies for cancer and other serious diseases.

Syndax Pharmaceuticals, Inc. entered into subscription agreements to issue $250.0 million of 2.25% Convertible Senior Notes due 2031. The company expects net proceeds of approximately $243 million to be used for general corporate purposes, including research and development and commercialization. The notes feature an initial conversion price of approximately $24.76 per share.